Stock on the Move for Monday: MEDP! June 9, 2008

MIAMI, FL , Amgen (NASDAQ: AMGN), Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Dendreon Corp. (NASDAQ: DNDN).

There is positive news coming from MedSpas of America, Inc. (PINKSHEETS: MEDP) and the company should have the attention of investors this morning. Friday after the markets closed, the company issued a press release announcing it has updated its worldwide agreement with Zymetech, Inc. from Reykjavick, Iceland, www.zymetech.com, for the use of Penzim as the essential ingredient in the anti-aging line of products for Natural Renu.

Great News for MEDP! Under the trademark of Penzim, Zymetech owns the worldwide patents for an active ingredient called Penzyme derived from enzymes produced by fish, particularly cod in the North Atlantic. This enzyme has been clinically tested for the treatment of pain, inflammation, arthritis, bursitis, eczema, psoriasis, fybromyalgia, acne and other skin conditions, such as itching, dry skin and brown spots.

The Supply Agreement provides the Company worldwide rights to sell Penzim under Natural Renu's trade name in the health and beauty care market sector. The term of the agreement is initially four years with automatic renewals of successive periods of two years at a time.

The new division will operate under the brand name of Natural Renu. The company will focus its sales efforts primarily through two marketing channels. The first and primary sales channel shall be the Internet. By utilizing its existing skill set and marketing prowess in this area, the company shall initiate an intensive online awareness campaign and drive potential users of this type of product to its web site. The second target audience shall be to exclusive Dayspas, Resorts and Medspas around the world.

Prior to the latest press release, the stock closed Friday at a Penny a share.

For Stock Market Alerts' in-depth profile of MedSpas of America, visit http://www.wallstreetenews.com/HotStocks/MEDP060808/default.aspx.

Other Stocks of interest yesterday were:

Amgen (NASDAQ: AMGN) down 1.5% on 7.8 million shares traded. Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) down 8.6% on 7.7 million shares traded. Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines.

Dendreon Corporation (NASDAQ: DNDN) down 3% on 1.3 million shares traded. Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer.

The advertisement is provided by Wall Street Enews, a division of Stock Market Alerts LLC, an electronic broadcaster and publisher of this release, and hereafter referred to as "the company." The company has not received compensation for services performed for MedSpas of America, Inc. (PINKSHEETS: MEDP). However, the company maintains a contractual working relationship with Wall Street Capital Funding (WSCF) which has been compensated Twenty Million shares of MedSpas of America Inc., by a third party (Trash Advertising Inc.), who is non-affiliated and may hold a significant position in the stock. WSCF holds all of those shares as of this release, but intends to immediately begin selling its shares as this release is being circulated. Because compensation was received, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The information contained in this press release is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. Stock Market Alerts LLC is an advertising company and therefore, this release should be viewed for informational purposes only.

The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the advertising information contained in this release as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the public company that this release is providing service for should be reviewed as speculative and a high-risk and may result in the loss of some or all of any investment.

This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

CONTACT: Stock Market Alerts LLC Email Contact

Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024